real-world efficacy of avelumab and axitinib in advanced renal cell carcinoma
Published 5 months ago • 70 plays • Length 0:44Download video MP4
Download video MP3
Similar videos
-
2:27
combining avelumab and axitinib in advanced renal cell carcinoma (rcc)
-
0:47
avelumab plus axitinib shows good efficacy for os and pfs in arcc patients
-
0:57
avelumab and axitinib for the treatment of advanced rcc
-
3:41
tide-a: avelumab and intermittent axitinib in metastatic renal cell carcinoma
-
5:10
real-world treatment outcomes of 1l axitinib pembrolizumab in patients with advanced rcc in the us
-
1:24
final results of avelumab and axitinib in rcc in the javelin renal 101 trial
-
3:30
promising results for axitinib and pembrolizumab in advanced renal cell cancer
-
4:39
avelumab and axitinib vs sunitinib in treating advanced renal cell carcinoma
-
2:32
avelumab plus axitinib improves survival in advanced renal-cell carcinoma patients
-
9:30
study on avelumab and axitinib vs sunitinib in the treatment of advanced renal cell carcinoma
-
2:31
axitinib plus pembrolizumab in advanced rcc
-
9:23
javelin renal 101: avelumab plus axitinib improve pfs for advanced renal cell cancer
-
1:59
real-world vs. clinical trial: efficacy of nivolumab in mrcc
-
1:00
pembrolizumab/axitinib and avelumab/axitinib combo for rcc
-
1:37
dr. shuch on caveats of avelumab/axitinib combination in rcc
-
4:25
kidney cancer updates: avelumab/axitinib, pembro/axitinib, bevacizumab/atezo & ipilimumab/nivo
-
1:55
belzutifan real-world vs clinical trial data: comparing efficacy and safety in vhl-associated tumors
-
1:29
phase i/ii study of nivolumab and axitinib for advanced rcc
-
6:38
efficacy of pd-l1 inhibitor avelumab in nepc/avpc